GKIM
GW&K Investment Management Portfolio holdings
AUM
$11.2B
1-Year Return
17.28%
This Quarter Return
+14.11%
1 Year Return
+17.28%
3 Year Return
+73.9%
5 Year Return
+156.73%
10 Year Return
+412.58%
AUM
$10.7B
AUM Growth
+$771M
(+7.7%)
Cap. Flow
-$392M
Cap. Flow
% of AUM
-3.66%
Top 10 Holdings %
Top 10 Hldgs %
11.77%
Holding
965
New
39
Increased
358
Reduced
400
Closed
21
Top Buys
| 1 |
Procore
PCOR
|
+$52.1M |
| 2 |
Tandem Diabetes Care
TNDM
|
+$36.3M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$31M |
| 4 |
Intapp
INTA
|
+$26.9M |
| 5 |
Tri Pointe Homes
TPH
|
+$24.4M |
Top Sells
| 1 |
Brookfield Infrastructure
BIPC
|
+$37.5M |
| 2 |
Manhattan Associates
MANH
|
+$35.5M |
| 3 |
Molina Healthcare
MOH
|
+$24.6M |
| 4 |
INN
Summit Hotel Properties
INN
|
+$22.5M |
| 5 |
Avantor
AVTR
|
+$20.3M |
Sector Composition
| 1 | Industrials | 19.36% |
| 2 | Technology | 17.97% |
| 3 | Healthcare | 15.88% |
| 4 | Financials | 12.7% |
| 5 | Consumer Discretionary | 12.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
CVS Health
CVS
$91B
| $41K | ﹤0.01% |
521
+4
| +0.8% | +$315 |
|
427
iShares Core MSCI Emerging Markets ETF
IEMG
$104B
| $41K | ﹤0.01% |
809
+209
| +35% | +$10.6K |
|
428
Citigroup
C
$179B
| $40K | ﹤0.01% |
786
+126
| +19% | +$6.41K |
|
429
Marsh & McLennan
MMC
$99.2B
| $40K | ﹤0.01% |
212
+8
| +4% | +$1.51K |
|
430
Ameriprise Financial
AMP
$46.5B
| $39K | ﹤0.01% |
102
+2
| +2% | +$765 |
|
431
Intuitive Surgical
ISRG
$168B
| $39K | ﹤0.01% |
116
-1
| -0.9% | -$336 |
|
432
Starbucks
SBUX
$95.3B
| $39K | ﹤0.01% |
403
+27
| +7% | +$2.61K |
|
433
Vertex Pharmaceuticals
VRTX
$102B
| $39K | ﹤0.01% |
96
+3
| +3% | +$1.22K |
|
434
Lam Research
LRCX
$134B
| $38K | ﹤0.01% |
480
+10
| +2% | +$792 |
|
435
TJX Companies
TJX
$156B
| $38K | ﹤0.01% |
401
+1
| +0.3% | +$95 |
|
436
United Parcel Service
UPS
$71.5B
| $38K | ﹤0.01% |
244
+45
| +23% | +$7.01K |
|
437
American Express
AXP
$226B
| $36K | ﹤0.01% |
190
-14
| -7% | -$2.65K |
|
438
CSX Corp
CSX
$60B
| $36K | ﹤0.01% |
1,042
+9
| +0.9% | +$311 |
|
439
Bristol-Myers Squibb
BMY
$96.1B
| $35K | ﹤0.01% |
683
-37
| -5% | -$1.9K |
|
440
Gilead Sciences
GILD
$144B
| $35K | ﹤0.01% |
432
+35
| +9% | +$2.84K |
|
441
Progressive
PGR
$143B
| $35K | ﹤0.01% |
219
+26
| +13% | +$4.16K |
|
442
RB Global
RBA
$21.6B
| $35K | ﹤0.01% |
522
| – | – |
|
443
Novo Nordisk
NVO
$241B
| $34K | ﹤0.01% |
326
| – | – |
|
444
Zoetis
ZTS
$66.4B
| $34K | ﹤0.01% |
172
+29
| +20% | +$5.73K |
|
445
Analog Devices
ADI
$122B
| $33K | ﹤0.01% |
168
-15
| -8% | -$2.95K |
|
446
Charter Communications
CHTR
$36B
| $33K | ﹤0.01% |
86
+1
| +1% | +$384 |
|
447
Elevance Health
ELV
$71B
| $33K | ﹤0.01% |
70
+4
| +6% | +$1.89K |
|
448
Lockheed Martin
LMT
$107B
| $33K | ﹤0.01% |
72
+17
| +31% | +$7.79K |
|
449
Mondelez International
MDLZ
$81B
| $33K | ﹤0.01% |
461
+11
| +2% | +$787 |
|
450
ProPetro Holding
PUMP
$471M
| $33K | ﹤0.01% |
3,910
-2,062,045
| -100% | -$17.4M |
|